In an exclusive interview, the former NBA star describes the change in his life as night and day. Tap through for how he talks about it.
Recap by typeshit. Full story at People.com.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
The endocrinologist explains that microdosing means taking far less than the doses recommended for treatment, and gives his view on the trend.
A link to the FDA's list of bulk drug substances it says may carry significant safety risks in compounding, relevant to the peptide policy fight.
Loading…